Zoetis Inc (ZTS) was Resumed by BofA/Merrill to “Buy”. BofA/Merrill advised their investors in a research report released on Sep 29, 2016.
On the company’s financial health, Zoetis Inc reported $0.49 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.44. The company had revenue of $1208.00 million for the quarter, compared to analysts expectations of $1169.42 million. The company’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.
Zoetis Inc opened for trading at $51.2 and hit $51.88 on the upside on Tuesday, eventually ending the session at $51.87, with a gain of 1.29% or 0.66 points. The heightened volatility saw the trading volume jump to 32,03,389 shares. Company has a market cap of $25,678 M.
In a different news, on Sep 6, 2016, Michael B Mccallister (director) purchased 2,000 shares at $51.34 per share price. According to the SEC, on Sep 2, 2016, Andrew Fenton (Executive Vice President) sold 13,870 shares at $51.25 per share price. On Sep 2, 2016, Heidi C. Chen (Executive Vice President) sold 32,097 shares at $50.98 per share price, according to the Form-4 filing with the securities and exchange commission.
Zoetis Inc. is engaged in the discovery development manufacture and commercialization of animal health medicines and vaccines with a focus on both livestock and companion animals. The Company markets products across four regions: the United States Europe/Africa/Middle East Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle swine poultry sheep and fish and the companion animal species of dogs cats and horses and five product categories: anti-infectives vaccines parasiticides medicated feed additives and other pharmaceutical products. In addition its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.